Ishares Msci Italy ETF vs Halozyme Therapeutics Inc. Common Stock — how do they compare? Ishares Msci Italy ETF trades at $56.32 (market cap $1.14B), while Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 11× Ishares Msci Italy ETF's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Ishares Msci Italy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Italy ETF for 53 Days and Halozyme Therapeutics Inc. Common Stock for 1 Days on average.
| EWI | HALO | |
|---|---|---|
Market Cap | $1.14B | $12.58B |
Volume | 2,377,947 | 2,179,278 |
Sector | Broad Market / Factor | Health |
52-Week High | $63.35 | $115.22 |
52-Week Low | $50.31 | $61.63 |
Typical Hold Time | 53 Days | 1 Days |
Enterprise Value | — | $14.49B |
Signals from Pluang's Aura AI — not financial advice
EWI (iShares MSCI Italy ETF) trades at $56.32, down slightly by 0.05% with a bearish technical signal from moving averages and oscillators. The ETF provides concentrated exposure to Italian financials, utilities, and industrials, benefiting from sector consolidation and EU recovery investments. Recent news highlights European Central Bank rate hikes and energy price pressures affecting eurozone markets.
The outlook remains cautious due to technical bearish signals and macroeconomic headwinds from ECB tightening. Investment opportunity lies in Italy's banking consolidation and infrastructure spending, but risks include eurozone economic sentiment deterioration and persistent inflation concerns.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
EWI is a country-specific ETF that tracks the performance of the Italian equity market. It provides targeted access to large and mid-sized companies in Italy, with a heavy focus on the financial sector and holdings like UniCredit and Intesa Sanpaolo.
Read more on EWI →Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →